Health Outcomes and Cost-effectiveness of Monoclonal SARS-CoV-2 Antibodies as Pre-exposure Prophylaxis.

ABSTRACT:

Importance

Pre-exposure prophylaxis with neutralizing SARS-CoV-2 monoclonal antibodies (mAbs PrEP) prevents infection and reduces hospitalizations and the duration thereof for COVID-19 and death among high-risk individuals. However, reduced effectiveness due to a changing SARS-CoV-2 viral landscape and high drug prices remain substantial implementation barriers.

Objective

To assess the cost-effectiveness of mAbs PrEP as COVID-19 PrEP.

Design, setting, and participants

For this economic evaluation, a decision analytic model was developed and parameterized with health care outcome and utilization data from individuals with high risk for COVID-19. The SARS-CoV-2 infection probability, mAbs PrEP effectiveness, and drug pricing were varied. All costs were collected from a

SUBMITTER: Popping S 

PROVIDER: S-EPMC10326646 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature